Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 25;37(5):994-999.
doi: 10.1093/ndt/gfac007.

Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study

Borja Quiroga  1 , María José Soler  2   3 , Alberto Ortiz  3   4 , Amparo Bernat  5 , Ana Beatriz Muñoz Díaz  5 , Carlos Jesús Jarava Mantecón  6 , Virginia Olinda Gómez Pérez  6 , Carmen Calderón González  7 , Michal Cervienka  7 , Auxiliadora Mazuecos  8 , Juan Manuel Cazorla  8 , Manuel Carnerero Di Riso  9 , Shaira Martínez  9 , Mayra Ortega Diaz  10 , Rafael Lucena Valverde  10 , María Gabriela Sánchez Márquez  11 , Carolina Lancho Novillo  11 , Emilio González Parra  4 , Carolina Gracia-Iguacel  4 , María Teresa Rodrigo De Tomas  12 , María Cinta Aguilar Cervera  12 , Martín Giorgi  1 , Patricia Muñoz Ramos  1 , Nicolás Macías Carmona  13 , Néstor Toapanta  2 , Secundino Cigarrán  14 , Juan Carlos Ruiz San Millán  15 , Raquel Santana Estupiñán  16 , Marta Crespo  17 , Blanca Villacorta Linaza  18 , María Isabel Jimeno Martín  19 , Laura Rodríguez-Osorio Jiménez  20 , Sagrario Soriano  21 , Dioné González Ferri  22 , María Soledad Pizarro Sánchez  23 , Alejandra Yugueros  24 , Alba Leyva  25 , José Rojas  25 , Ron T Gansevoort  26 , Patricia de Sequera  3   10 ; SENCOVAC collaborative network
Collaborators, Affiliations

Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study

Borja Quiroga et al. Nephrol Dial Transplant. .
No abstract available

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
(A) Flow chart of the SENCOVAC study. (B) Proportion of patients with positive humoral response at baseline, 28 days and 3 months. (C) Negative and equivocal humoral response 3 months after completing vaccine schedule among patients with positive humoral response at 28 days. Data expressed as percentage of those who were positive at 28 days.
See this image and copyright information in PMC

References

    1. Quiroga B, Soler MJ, Ortiz Aet al. . (12 November 2021) Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrol Dial Transplant; doi: 10.1093/ndt/gfab313 - PMC - PubMed
    1. Puranik A, Lenehan PJ, Silvert Eet al. . Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med (N Y) 2022; 3: 28–41.e8 - PMC - PubMed
    1. Embi PJ, Levy ME, Naleway ALet al. . Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults—nine states, January–September 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1553–1559 - PMC - PubMed
    1. Vergara A, Molina-Van den Bosch M, Toapanta Net al. . The impact of age on mortality in chronic haemodialysis population with COVID-19. J Clin Med 2021; 10: 3022. - PMC - PubMed
    1. Müller L, Andrée M, Moskorz Wet al. . Age-dependent immune response to the biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin Infect Dis Clin Infect Dis 2021; 73: 2065–2072 - PMC - PubMed

Publication types